Byron J. Allen

Health Sciences Professor
School of Medicine

M.D., University of California, Los Angeles, 1980

Phone: (714) 456-6699
Fax: (714) 456-8895

University of California, Irvine
101 The City Drive
Mail Code: 4080
Orange, CA 92868

Cardiology, Congestive Heart Failure, Cardiac transplantation, Arrhythmias, Coronary artery disease.
Clinical application of new therapies for heart failure and arrhythmias.
Publications Orlov YSK, Brodsky MA, Orlov MV, Allen BJ, Winters R. Is the time domain signal-averaged electrocardiogram helpful in patients with ventricular tachycardia without apparent structural heart disease: Clin Cardiol 18:568-572, 1995
  Brodsky MA, Orlov MV, Allen BJ, Orlov YSK, Wolff L, Winters R. Clinical assessment of adrenergic tone and responsiveness to beta blocker therapy in patients with symptomatic ventricular tachycardia and no apparent structural heart disease. AM Heart J 131:51-58, 1996
  Orlov MV, Brodsky MA, Allen B. Electrocardiographic evidence of myocardial infarction in preexcitation pre and post ablation. J Electrocardiol 29:49-54, 1996.
  Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R. Regional attitudes of generalists, specialists and subspecialists about management of atrial fibrillation. Arch Intern Med 156:1553-2562, 1996
  Orlov YSK, Brodsky MA, Orlov MV, Allen B. Near doubling of heart rate after intravenous verapamil for treatment of atrial fibrillation without preexcitation. Pacing Clin Electrophysiol 20:2867-2869, 1997.
  Kasravi B, Reid CL, Allen BJ. Coronary artery fistula presenting as bacterial endocarditis. J Am Soc Echocardiogr 17:1315-1316, 2004.
Grants Principal Investigator, Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry.
Co-Principal Investigator, The Level of Practitioners Adherence With American Diabetes Association (ADA) Guidelines for Lipid Management in Patients With Diabetes in a Specialty Clinic.
Principal Investigator, Organized Program to Initiate Life-Saving Treatment in Hospitalized Patients with Heart Failure (Optimize-HF).
Principal Investigator, A Phase IIIb, Randomized, Open Label Trial with 3 Parallel Groups: Full Dose TNK-tPA Together with Heparin Sodium; Full Dose TNK-tPA Together with Enoxaparin; and Half Dose TNK-tPA with Abciximab and Heparin Sodium in Patients with Acute Myocardial Infarction – Assent 3 (Assessment of Safety and Efficacy of New Thrombolytic Regimens.
Principal Investigator, Discovery of Gene Mutations and Polymorphisms that Contribute to the Risk of Arteriosclerosis.
International Society of Heart and Lung Transplantation
Heart Failure Society of America
Graduate Programs Cardiovascular Disease (IM)

Link to this profile
Last updated 02/06/2007